Sunscreen labels may still be confusing to majority of consumers
the ONA take:
According to results of a small study published online ahead of print in JAMA Dermatology, researchers have found that sunscreen labels may still be confusing to the majority of consumers.
For the study, researchers from Northwestern University Feinberg School of Medicine in Chicago surveyed 114 patients at a single dermatology clinic to evaluate their understanding of sunscreen labels and best practices for sun protection.
Results showed that 81.6% reported purchasing sunscreen in 2013. Of all participants, 75.4% said they purchased sunscreen in order to prevent sunburns and 65.8% bought it to prevent skin cancer.
Researchers found that only 43% understood the definition of SPF, 37.7% could correctly determine how well the sunscreen protected against skin cancer, and 22.8% could correctly identify how well the sunscreen protected against sunburns.
The findings suggest that sunscreen label terminology may still be confusing to the majority of consumers seeking to protect themselves from sunburns and skin cancer.
Sunscreen labels may still be confusing to the majority of consumers.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|